48,990
edits
Line 97: | Line 97: | ||
</gallery> | </gallery> | ||
===Histological subtyping=== | ===Histological subtyping - historical=== | ||
Historically, PaRCC was subtyped:<ref name=Ref_GUP289>{{Ref GUP|289}}</ref><ref>{{Cite journal | last1 = Delahunt | first1 = B. | last2 = Eble | first2 = JN. | title = Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. | journal = Mod Pathol | volume = 10 | issue = 6 | pages = 537-44 | month = Jun | year = 1997 | doi = | PMID = 9195569 }}</ref> | Historically, PaRCC was subtyped:<ref name=Ref_GUP289>{{Ref GUP|289}}</ref><ref>{{Cite journal | last1 = Delahunt | first1 = B. | last2 = Eble | first2 = JN. | title = Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. | journal = Mod Pathol | volume = 10 | issue = 6 | pages = 537-44 | month = Jun | year = 1997 | doi = | PMID = 9195569 }}</ref> | ||
*''Type 1'' - single layer of cells on basement membrane - '''most important'''. | *''Type 1'' - single layer of cells on basement membrane - '''most important'''. | ||
Line 113: | Line 113: | ||
The WHO GU Blue Book 5th Ed. recommends against subtyping. | The WHO GU Blue Book 5th Ed. recommends against subtyping. | ||
The defunct ''Type 1'' is papillary renal cell carcinoma. It is classically associated with a MET gene alteration. | |||
The defunct ''Type 2'' is a mix of other tumour, e.g. ALK-RCC, translocation RCC, FH-deficient RCC. | |||
Another subtype: | Another subtype: |
edits